
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Treatment of Refractory Metastatic Renal Cell Carcinoma
A 70-Year-Old African-American Woman with Metastatic RCC
December 2017
June 2018
